Discovery of MMP activated peptide-doxorubicin prodrugs as anti-tumor agents: Part I

被引：0

作者：

Han, Wei

Jiang, XiangJun

Hu, Zilun

Graciani, Nilsa

Albright, Charles F.

Yue, Eddy

Zhang, Mingzhu

Dowling, Randine

Huang, Pearl

Oliff, Allen

Copeland, Robert A.

Trainor, George L.

Combs, Andrew P.

Seitz, Steven P.

机构：

[1] Bristol Myers Squibb, Pharmaceut Res Inst, Princeton, NJ 08543 USA

[2] GlaxoSmithKline Inc, Stevenage, Herts, England

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2006年 / 231卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

271-MEDI

引用

页数：2

共 50 条

[21] RADIATION MODULATES THE PEPTIDE REPERTOIRE, ENHANCING MHC CLASS I EXPRESSION AND IMPROVING ANTI-TUMOR IMMUNO-THERAPY [J].

Neefjes, J. ;

Qiao, X. ;

Pang, B. .

RADIOTHERAPY AND ONCOLOGY, 2008, 88 :S168-S168

[22] Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity [J].

Zhao, Yang ;

Ren, Wei ;

Zhong, Ting ;

Zhang, Shuang ;

Huang, Dan ;

Guo, Yang ;

Yao, Xin ;

Wang, Chao ;

Zhang, Wei-Qiang ;

Zhang, Xuan ;

Zhang, Qiang .

JOURNAL OF CONTROLLED RELEASE, 2016, 222 :56-66

[23] LABELED COMPOUNDS OF INTEREST AS ANTI-TUMOR AGENTS-I - N-METHYLFORMAMIDE AND N,N-DIMETHYLFORMAMIDE [J].

THREADGILL, MD ;

GATE, EN .

JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 1983, 20 (04) :447-451

[24] Anti-tumor activity of naive and activated class I-restricted tumor-specific TCR-transgenic T cells. [J].

Dalyot-Herman, N ;

Malek, TR .

FASEB JOURNAL, 1999, 13 (04) :A613-A613

[25] CLINICAL IMPLICATIONS OF THE INVITRO CYTO-TOXIC ACTIVITY OF PRE-CLINICAL AND PHASE-I ANTI-TUMOR AGENTS [J].

HOLLAND, JC ;

BAHNA, G ;

MCKEGNEY, P ;

SILBERFARB, P ;

TROSS, S ;

GLIDEWELL, O .

PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR) :354-354

[26] Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice [J].

Sultan, Hussein ;

Wu, Juan ;

Kumai, Takumi ;

Salazar, Andres M. ;

Celis, Esteban .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (07) :1091-1103

[27] Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice [J].

Hussein Sultan ;

Juan Wu ;

Takumi Kumai ;

Andres M. Salazar ;

Esteban Celis .

Cancer Immunology, Immunotherapy, 2018, 67 :1091-1103

[28] EFFECT OF MATRIX METALLOPROTEINASE (MMP)-3,-8,-10 AND-12 ON THE STRUCTURE AND FUNCTION OF ANTI-TUMOR NECROSIS FACTOR-ALPHA AGENTS IN INFLAMMATORY BOWEL DISEASE [J].

Biancheri, P. ;

Di Sabatino, A. ;

Snoek, S. A. ;

Joe-njoku, I. ;

Rovedatti, L. ;

Ahmad, N. ;

Corazza, G. R. ;

Macdonald, T. T. .

DIGESTIVE AND LIVER DISEASE, 2011, 43 :S132-S132

[29] AB308 IS AN ANTI-TIGIT ANTIBODY THAT ENHANCES IMMUNE ACTIVATION AND ANTI-TUMOR IMMUNITY ALONE AND IN COMBINATION WITH OTHER I-O THERAPEUTIC AGENTS [J].

Piovesan, Dana ;

Lopez, Alejandra ;

Schweickert, Patrick ;

Soriano, Ferdie ;

Cho, Soonweng ;

Chen, Ada ;

Singh, Hema ;

Zhao, Xiaoning ;

Young, Stephen ;

Walker, Nigel ;

Walters, Matthew ;

Gauthier, Kelsey Sivick .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 :A280-A280

[30] Treatment With Anti-Tumor Necrosis Factor Biologic Agents in Human T Lymphotropic Virus Type I-Positive Patients With Rheumatoid Arthritis [J].

Umekita, Kunihiko ;

Hidaka, Toshihiko ;

Miyauchi, Shunichi ;

Ueno, Shiro ;

Kubo, Kazuyoshi ;

Takajo, Ichiro ;

Hashiba, Yayoi ;

Kai, Yasufumi ;

Nagatomo, Yasuhiro ;

Okayama, Akihiko .

ARTHRITIS CARE & RESEARCH, 2014, 66 (05) :788-792

← 1 2 3 4 5 →